[Current status and future developments in chemotherapy of advanced epithelial ovarian cancers (author's transl)].
In the management of advanced epithelial cancers of the ovary the importance of prognostically significant factors is well established. The remission rates with the drugs most commonly used are stated. Patients with a complete remission show a marked increase in survival time. The importance of prior chemotherapy in relation to a second or third line of treatment is discussed. Immunological test series in combination with chemotherapy are undergoing controlled investigations.
D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy; D003536:Cystadenocarcinoma / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis
D000970:Antineoplastic Agents
Stand und Entwicklung in der Chemotherapie fortgeschrittener epithelialer Ovarialkarzinome.